The latest round of bidding for the generic drug business of Germany's Merck KGaA pushed offers over the €4 billion ($5.4 billion) mark, according to a report in the Financial Times. Four bidding groups are still in the competition: Teva, Mylan, Actavis and a pair of private equity firms--Apax Partners and Bain Capital. Merck officials said as late as last Friday that no final decision on a sale had been made and the amount of financial information being made available to would-be buyers is still limited. Another round of bidding may be forthcoming.
- read the AFX report [1] on the bidding
Related Articles:
New bid rumors heat up Merck KGaA stock. Report [2]
Bidding war heats up for Merck KGaA generic unit. Report [3]
Merck KGaA shortens list of bidders for drug unit. Report [4]
Ranbaxy touts R&D abilities in new discovery pact. Report [5]
Links:
[1] http://www.forbes.com/markets/feeds/afx/2007/05/01/afx3670889.html
[2] http://www.fiercebiotech.com/story/new-bid-rumors-heat-up-merck-kgaa-stock/2007-03-08
[3] http://www.fiercebiotech.com/story/bidding-war-heats-up-for-merck-kgaa-generic-unit/2007-03-13
[4] http://www.fiercebiotech.com/story/merck-kgaa-shortens-list-of-bidders-for-drug-unit/2007-03-16
[5] http://www.fiercebiotech.com/story/ranbaxy-touts-rd-abilities-in-new-discovery-pact/2007-02-07